Cutaneous innate immune and inflammatory pathways

Cutaneous innate immune and inflammatory pathways represent the integrated network of sensors and effectors that protect the skin from environmental threats and maintain tissue homeostasis (Pasparakis et al., 2014, Nature Reviews Immunology). These pathways are initiated by the recognition of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) by pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs), on keratinocytes and resident immune cells (Dainichi et al., 2018, J Dermatol Sci). Activation leads to the production of pro-inflammatory cytokines like TNF-alpha, IL-1, and IL-6, which recruit and activate further immune cells like neutrophils and T-cells. In chronic conditions like psoriasis and atopic dermatitis, these pathways become pathologically persistent, often driven by specific axes like the IL-23/IL-17 or IL-4/IL-13 cascades (Nestle et al., 2009, NEJM). Pharmacological targeting of these pathways involves biologics and small molecules that inhibit specific cytokines or intracellular signaling nodes, such as Janus kinases (JAKs), to dampen the inflammatory response and restore the skin barrier.

Other names

Skin immune systemCutaneous inflammatory cascadeInnate immunity of the skinCutaneous immune response

Drugs targeting these pathways typically act by neutralizing specific pro-inflammatory cytokines (e.g., IL-17, IL-23, IL-4, IL-13), inhibiting intracellular signaling transducers (e.g., JAK proteins), or modulating pattern recognition receptor activity to dampen the overactive immune response in the skin.